European Medicines Agency – News and Events – Committee for Orphan Medicinal Products: Chair and Vice-chair re-elected

European Medicines Agency – News and Events – Committee in favor of Orphan Medicinal Products: Chair and Vice-professorship re-elected


Felicidades a Lesley Greene y Bruno Sepodes por su reelección como vicepresidenta y presidente del Comité de Medicamentos Huérfanos


Committee ~ the sake of Orphan Medicinal Products: Chair and Vice-chairman re-elected

Bruno Sepodes and Lesley Greene appointed conducive to new three-year mandate

Bruno_ Leslie and Lesley GreeneAt its October 2015 joining, the European Medicines Agency’s (EMA’s)Committee beneficial to Orphan Medicinal Products (COMP) voted to recreate the mandates of Professor Bruno Sepodes and Ms Lesley Greene (one as well as the other pictured) as chair and vice-presiding officer respectively. Both of their terms hold been prolonged by three years, initiation this month.

Professor Sepodes is a Professor of Pharmacology and Pharmacotherapy at the Faculty of Pharmacy of the University of Lisbon. He became a member of theCOMP in 2008 and has served like chair of the committee since 2012. Ms Lesley Greene joined the COMP in 2009. She is a proffer patient representative for EurordisExternal link icon and has a slow history in patient advocacy, having established a constant organisation for rare metabolic diseases in 1981. Since the in all its senses of the committee in 2001, the defect-chair has always been a deputy of a patient organisation. This highlights the weight of the contribution of civil the world to the work of the COMP.

Accepting his re-appointment by vote, Professor Sepodes said, “It is some immense privilege to be given the opportunity to discharge the requirements of the COMP for a further three years. The COMP is a data-driven scientific committee, and looking forward, I would like to maintain our according to principles mission as the main driver of our drudge, thanks to the expertise of our committee members and their imprisonment to addressing the unmet medical indispensably of patients with orphan diseases. The increasing levels of involved character of new applications for medicines set apart for deeper cooperation between the COMP and other EMA committees, specifically in the areas of advanced therapies and paediatric medicines. In this scheme, we can ensure that we catalyse orphan mix with ~s development. I look forward to playing a key role in these interactions.”

Professor Sepodes sees brace key priorities for the COMP:

continuing maintain for the active participation of patients’ representatives, not sole as full members of the COMP, moreover also as observers and experts; and

strengthening interactions with multiple stakeholders and regulatory magistrates globally.

The COMP is the committee at EMA liable for reviewing applications from people or companies seeking orphan description. Orphan designation can be granted forward in the development process to substances that are intended according to the diagnosis, prevention or treatment of life-threatening or very serious conditions that feign not more than 5 in 10,000 the public in the European Union or that would not be developed without incentives.

Workers union bond of duty saladin muhammad hit that beacon center has published cells from used care nature sales.

Recent Comments